ADVERTISEMENT
Search

April 2024

Pharmacy Today logo
Volume 30, Issue 4

Archives   Download TOC  

Current Issue

April 2024 cover

Download  

ADVERTISEMENT
 

Practice & Trends

Health care teams for gender-affirming care have a clear place for pharmacists

On The Cover

Health care teams for gender-affirming care have a clear place for pharmacists

Hormone therapy, specifically estradiol and testosterone, are familiar drugs. Pharmacists know how they interact with other medications. What is less clear is how pharmacists fit into the changing landscape of clinics and health care teams as transgender individuals seek gender-affirming hormone therapy, a medical intervention to align appearance with gender identity.

Loren Bonner & Clarissa Chan, PharmD

 
RSS
News Roundup
Bulletin Today

Bulletin Today

News Roundup

FDA warns patients not to use smartwatches or smart rings to measure blood glucose levels. Survey looks at characteristics of young adults who use e-cigarettes. CDC: Older adults should get another COVID-19 dose this spring. BP improves with patients taking GLP-1, says study. Low-dose aspirin during pregnancy appears to have no effect on child’s neurodevelopment. Age-related risk of serious falls increases with opioid use. Pennsylvania pharmacists can now bill Medicaid for pharmacy services. 

RSS

Drugs & Diseases

Prebiotics: A gut check

On The Shelf

Prebiotics: A gut check

Prebiotic dietary supplements boast that they promote digestive health, reduce inflammation, increase energy and drive, and may help with appetite control. All this and they're also vegan, gluten-free, sugar-free, and keto-friendly. What are prebiotics, anyway?

Mickie Cathers

Muscle aches and pain

OTCs Today

Muscle aches and pain

Everyone experiences muscle pain (myalgia) at some point in their lives, whether due to overexertion, injury, or disease. Fortunately, numerous options, including 1·est, massage, and medications, are available to relieve the pain.

Mary Warner

 

RSS

Health Systems

RSS

CPE

New therapeutic agents marketed in 2023: Part 1
CPE

CPE

New therapeutic agents marketed in 2023: Part 1

FDA approved 55 new drugs in 2023. Twenty-eight (51%) of these new drugs received orphan drug designation because they are used in the treatment of patients with rare diseases. Five new therapeutic agents are considered in this review, the first in a two-part series of articles on new therapeutic agents approved in 2023: bexagliflozin (Brenzavvy-TheracosBio ), sotagliflozin (lnpefa- Lexicon), zavegepant hydrochloride (Zavzpret- Pfizer)/ lecanemab-irmb (Leqembi-Eisai; Biogen), and fezolinetant (Veozah-Astellas).

Daniel A. Hussar, PhD

RSS

In this Issue

ADVERTISEMENT